Clinuvel Pharmaceuticals Limited Stock Xetra
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded| Market Cap | 422M 301M 260M 246M 223M 418M 28.84B 2.94B 1.13B 14.62B 1.13B 1.1B 46.64B | P/E 2027 * |
11.8x | P/E 2028 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise Value | 138M 98.19M 85.05M 80.42M 72.81M 137M 9.42B 960M 369M 4.78B 369M 361M 15.23B | EV / Sales 2027 * |
1.45x | EV / Sales 2028 * | 1.01x |
| Free-Float |
83.79% | Yield 2027 * |
0.65% | Yield 2028 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 299M | |
| -2.47% | -4.47% | +35.19% | -5.99% | 79.26B | |
| -1.99% | +2.45% | +502.05% | +25.46% | 58.56B | |
| +0.05% | +1.61% | -13.84% | -34.52% | 58.62B | |
| -0.56% | -1.94% | -11.70% | +25.63% | 48.75B | |
| -0.29% | +1.45% | +2.14% | +149.29% | 46.32B | |
| -0.55% | +1.73% | +50.83% | -15.16% | 32.12B | |
| -0.37% | -2.14% | +46.43% | +94.63% | 24.77B | |
| -1.91% | -5.19% | -0.63% | +142.35% | 21.5B | |
| -1.92% | -3.81% | +61.03% | +96.07% | 15.97B | |
| Average | -0.70% | -1.05% | +74.61% | +53.09% | 42.87B | |
| Weighted average by Cap. | -0.71% | -1.12% | +89.81% | +35.27% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 67.65M 58.6M 55.41M 50.17M 94.16M 6.49B 661M 254M 3.29B 254M 248M 10.49B | 103M 73.48M 63.64M 60.18M 54.48M 102M 7.05B 718M 276M 3.57B 276M 270M 11.4B |
| Net income | 36.02M 25.69M 22.25M 21.04M 19.05M 35.75M 2.46B 251M 96.59M 1.25B 96.48M 94.34M 3.98B | 38.1M 27.17M 23.54M 22.26M 20.15M 37.82M 2.61B 266M 102M 1.32B 102M 99.8M 4.21B |
| Net Debt | -284M -202M -175M -166M -150M -282M -19.42B -1.98B -761M -9.85B -761M -744M -31.41B | -317M -226M -196M -185M -168M -315M -21.71B -2.21B -851M -11.01B -850M -831M -35.1B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
